137 related articles for article (PubMed ID: 31385336)
1. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
3. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
[TBL] [Abstract][Full Text] [Related]
4. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of orally administered
MacDonald A; Scarfe G; Magirr D; Sarvotham T; Charlton J; Brugger W; Dean E
Cancer Chemother Pharmacol; 2019 Apr; 83(4):787-795. PubMed ID: 30758651
[TBL] [Abstract][Full Text] [Related]
7. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.
Oki Y; Kelly KR; Flinn I; Patel MR; Gharavi R; Ma A; Parker J; Hafeez A; Tuck D; Younes A
Haematologica; 2017 Nov; 102(11):1923-1930. PubMed ID: 28860342
[TBL] [Abstract][Full Text] [Related]
8. A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP; Clevenger TN; Burke KA; Yang B; MacDonald A; Cunningham D; Fox CP; Goy A; Gribben J; Nowakowski GS; Roschewski M; Vose JM; Vallurupalli A; Cheung J; Raymond A; Nuttall B; Stetson D; Dougherty BA; Schalkwijk S; Carnevalli LS; Willis B; Tao L; Harrington EA; Hamdy A; Izumi R; Pease JE; Frigault MM; Flinn I
Leuk Lymphoma; 2021 Nov; 62(11):2625-2636. PubMed ID: 34269152
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
15. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
16. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
18. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
19. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
20. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B; Thieblemont C; de Guibert S; Dupuis J; Ribrag V; Bouabdallah R; Morschhauser F; Navarro R; Le Gouill S; Haioun C; Houot R; Casasnovas O; Holte H; Lamy T; Broussais F; Payrard S; Hatteville L; Tilly H
Br J Haematol; 2016 Jun; 173(5):722-30. PubMed ID: 27010483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]